Overall, these multifunctional TGF-β pathway-targeting fusion proteins exhibit a good efficacy and manageable safety profile in patients with a range of advanced solid tumours and can therefore have the potential to be developed into effective cancer immunotherapeutic agents [153,154]. This evidence concerns the gene TGFB1 and cancer.